Non-Small Cell Lung Cancer Coverage from Every Angle


Study Finds Link Between Guideline Adherence and Survival in NSCLC
Atezolizumab Plus Bevacizumab: A Potential Option for Certain Patients With Nonsquamous Lung Cancer
Immune Checkpoint Inhibitors and Lung Cancer: Tumor Vasculature–Based Imaging Biomarker
FDA Approves Pembrolizumab as Adjuvant Therapy for NSCLC
Radiation and Immunotherapy Given Together May Be of Benefit for Some Patients With Lung Cancer
Adding a Novel Antibody to Anti–PD-1 Immunotherapy for Metastatic NSCLC
Neoadjuvant Atezolizumab: Focus of National Study in Resectable NSCLC
FDA Brief: Companion Diagnostic Approved for Tyrosine Kinase Inhibitor Treatment of NSCLC
Plasma T-Cell–Derived Circulating DNA Levels With Immunotherapy for Advanced-Stage NSCLC
FDA Brief: Accelerated Approval Granted for Adagrasib in KRAS G12C–Mutated Lung Cancer
I-ELCAP Trial Shows Long-Term Survival Benefits of Lung Cancer Screening
Can the Lung-MAP Composite Signature Predict Outcomes With Immunotherapy in NSCLC?
Can CD8-Positive, FoxP3-Positive Cells Predict Immunotherapy Response in NSCLC?
SITC 2022: Immunity Hubs and Response to Immunotherapy in NSCLC
SITC 2022: Outcomes of Combination Therapy for Advanced NSCLC Stratified by KRAS Status
SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?
SITC 2022: First-Line Antigen Presenting Cell Activator Plus Pembrolizumab Under Study in NSCLC
SITC 2022: Can ctDNA Help to Predict Therapeutic Outcomes in Patients With NSCLC?
FDA Approves Combination Immunotherapy Regimen Plus Chemotherapy for Metastatic Lung Cancer
SITC 2022: Use of Cell-Free DNA Monitoring to Predict Outcomes With Immunotherapy in NSCLC
ASTRO 2022: Can Clinical Variables Predict Polymetastasis in Oligometastatic NSCLC?
ASTRO 2022: Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage NSCLC
Cempilimab-rwlc Plus Chemotherapy Receives FDA Approval in NSCLC
ASTRO 2022: Is Radiotherapy Safe for Cardiac Structures in Patients With Locally Advanced NSCLC?
Neoadjuvant Use of Ipilimumab Plus Nivolumab and Chemoradiotherapy for NSCLC
ASTRO 2022: Overall Time of Chemoradiotherapy and Outcomes in Stage III Lung Cancer
ASTRO 2022: Phase III Trial Compares Radiotherapy Regimens for Early-Stage NSCLC
ASTRO 2022: 2-Year KEYNOTE-799 Update on Pembrolizumab Plus Chemoradiotherapy in Stage III NSCLC
Can Weight Gain Improve Clinical Outcomes for Patients With Advanced NSCLC?
Impact of Low-Dose CT Screening on Lung Cancer Incidence and Stage Migration
Overall Survival Analysis From Phase III JIPANG Trial in Nonsquamous Lung Cancer
Shorter Duration of Treatment With Nivolumab Plus Ipilimumab in Advanced NSCLC
Molecular Profiling of Patients With Progressive NSCLC After Osimertinib Treatment
FDA Grants Fast Track Designation to Sapanisertib in Treatment of Squamous Lung Cancer
Mechanisms Behind NSCLC Associated With Exposure to the Air Pollutant Particulate Matter
ASCO Quality 2022: Are Mortgage Denial Rates Associated With Receipt of Guideline-Concordant Care in Lung Cancer?
ESMO 2022: Novel Bispecific Antibody Plus Chemotherapy Under Study in NSCLC
Can a Liquid Biomarker Augment Early Screening for Lung Cancer?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.